SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease

Overview

Journal GastroHep

Publisher Wiley

Specialty Gastroenterology

Date 2021 Sep 20

PMID 34539248

Citations 8

Authors

Ralley E Prentice

Clarissa Rentsch

Aysha H Al-Ani

Eva Zhang

Douglas Johnson

John Halliday

Robert Bryant

Jacob Begun

Mark G Ward

Peter J Lewindon

Susan J Connor

Simon Ghaly

Britt Christensen

Affiliations

Soon will be listed here.

Abstract

Background: The current COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), has drastically impacted societies worldwide. Vaccination against SARS-CoV-2 is expected to play a key role in the management of this pandemic. Inflammatory conditions such as inflammatory bowel disease (IBD) often require chronic immunosuppression, which can influence vaccination decisions.

Aim: This review article aims to describe the most commonly available SARS-CoV-2 vaccination vectors globally, assess the potential benefits and concerns of vaccination in the setting of immunosuppression and provide medical practitioners with guidance regarding SARS-CoV-2 vaccination in patients with IBD.

Methods: All published Phase 1/2 and/or Phase 3 and 4 studies of SARS-CoV-2 vaccinations were reviewed. IBD international society position papers, safety registry data and media releases from pharmaceutical companies as well as administrative and medicines regulatory bodies were included. General vaccine evidence and recommendations in immunosuppressed patients were reviewed for context. Society position papers regarding special populations, including immunosuppressed, pregnant and breast-feeding individuals were also evaluated. Literature was critically analysed and summarised.

Results: Vaccination against SARS-CoV-2 is supported in all adult, non-pregnant individuals with IBD without contraindication. There is the potential that vaccine efficacy may be reduced in those who are immunosuppressed; however, medical therapies should not be withheld in order to undertake vaccination. SARS-CoV-2 vaccines are safe, but data specific to immunosuppressed patients remain limited.

Conclusions: SARS-CoV-2 vaccination is essential from both an individual patient and community perspective and should be encouraged in patients with IBD. Recommendations must be continually updated as real-world and trial-based evidence emerges.

Citing Articles

COVID-19 vaccine updates for people under different conditions.

Huang Y, Wang W, Liu Y, Wang Z, Cao B Sci China Life Sci. 2024; 67(11):2323-2343.

PMID: 39083202 DOI: 10.1007/s11427-024-2643-1.

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination.

Resal T, Bacsur P, Horvath M, Szanto K, Rutka M, Balint A Therap Adv Gastroenterol. 2023; 16:17562848231183529.

PMID: 37461738 PMC: 10350576. DOI: 10.1177/17562848231183529.

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease.

Bronsky J, Copova I, Durilova M, Kazeka D, Kubat M, Lerchova T J Pediatr Gastroenterol Nutr. 2023; 76(2):e36-e44.

PMID: 36705698 PMC: 9847686. DOI: 10.1097/MPG.0000000000003661.

Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study.

Wasserbauer M, Hlava S, Trojanek M, Stovicek J, Milota T, Drabek J PLoS One. 2022; 17(9):e0273612.

PMID: 36054100 PMC: 9439210. DOI: 10.1371/journal.pone.0273612.

COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).

Kubas A, Malecka-Wojciesko E J Clin Med. 2022; 11(9).

PMID: 35566802 PMC: 9104993. DOI: 10.3390/jcm11092676.

References

Mamula P, Markowitz J, Piccoli D, Klimov A, Cohen L, Baldassano R . Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5(7):851-6. DOI: 10.1016/j.cgh.2007.02.035. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Sempere L, Almenta I, Barrenengoa J, Gutierrez A, Villanueva C, de-Madaria E . Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013; 31(30):3065-71. DOI: 10.1016/j.vaccine.2013.04.059. View

Young Chung J, Thone M, Kwon Y . COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2020; 170:1-25. PMC: 7759095. DOI: 10.1016/j.addr.2020.12.011. View

Gelinck L, van der Bijl A, Beyer W, Visser L, Huizinga T, van Hogezand R . The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2007; 67(5):713-6. DOI: 10.1136/ard.2007.077552. View

Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G . Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015; 30(11):1591-5. DOI: 10.1111/jgh.13001. View

Kapetanovic M, Saxne T, Truedsson L, Geborek P . Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther. 2013; 15(1):R1. PMC: 3672713. DOI: 10.1186/ar4127. View

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

Alexander J, Moran G, Gaya D, Raine T, Hart A, Kennedy N . SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021; 6(3):218-224. PMC: 7834976. DOI: 10.1016/S2468-1253(21)00024-8. View

10.

Wong P, Bagga H, Barrett C, Hanrahan P, Johnson D, Katrib A . A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. Intern Med J. 2017; 47(5):491-500. DOI: 10.1111/imj.13371. View

11.

Tse F, Moayyedi P, Waschke K, MacMillan M, Forbes N, Carroll M . COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology. J Can Assoc Gastroenterol. 2021; 4(1):49. PMC: 7898369. DOI: 10.1093/jcag/gwaa046. View

12.

Caldera F, Hillman L, Saha S, Wald A, Grimes I, Zhang Y . Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. Inflamm Bowel Dis. 2019; 26(4):593-602. DOI: 10.1093/ibd/izz164. View

13.

Brodmerkel C, Wadman E, Langley R, Papp K, Bourcier M, Poulin Y . Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013; 12(10):1122-9. View

14.

Ungaro R, Brenner E, Gearry R, Kaplan G, Kissous-Hunt M, Lewis J . Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2020; 70(4):725-732. PMC: 8136807. DOI: 10.1136/gutjnl-2020-322539. View

15.

Farshidpour M, Charabaty A, Mattar M . Improving immunization strategies in patients with inflammatory bowel disease. Ann Gastroenterol. 2019; 32(3):247-256. PMC: 6479655. DOI: 10.20524/aog.2019.0351. View

16.

Attauabi M, Seidelin J, Burisch J . Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?. Gut. 2021; 70(10):2020-2022. DOI: 10.1136/gutjnl-2021-324397. View

17.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

18.

Askling H, Rombo L, van Vollenhoven R, Hallen I, Thorner A, Nordin M . Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014; 12(2):134-42. DOI: 10.1016/j.tmaid.2014.01.005. View

19.

Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View

20.

Scribano M . Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018; 24(23):2457-2467. PMC: 6010939. DOI: 10.3748/wjg.v24.i23.2457. View